Pemetrexed sensitizes cisplatin therapy by inducing ferroptosis in NSCLC cells
Frontiers in Pharmacology · 21.01.2026 · 16
DOI: 10.3389/fphar.2025.1764937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.01.2026. Verfasst von Yumin Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, Ch…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cisplatin (DDP) is the first-in-class drug for advanced and non-targetable non-small-cell lung cancer (NSCLC). Platinum-based chemotherapy combined with pemetrexed (PEM) is frequently recommended as the first-line therapeutic regimen for NSCLC. However, the mechanisms of how PEM boosts the antitumor activity of DDP are largely unknown. Emerging evidence indicated that DDP could induce ferroptosis, a new type of regulated cell death (RCD) characterized by iron-dependent toxic build-up of lipid peroxides on cellular membranes. It is tempting to speculate whether PEM increases the sensitivity of NSCLC to DDP through inducing ferroptosis.
Methods
In the present study, we first used RNA-seq and KEGG analysis to examine differentially expressed genes in PEM-challenged NSCLC cells. The effect of PEM on increased DDP-mediated anticancer activity was examined via a cytotoxicity assay and Western blot. PEM-triggered ferroptosis in DDP-treated NSCLC was observed via a lipid peroxidation assay, a labile iron pool assay, and a Western blot in the presence or absence of ferroptosis inhibitors.
Results
In the present study, we found that the ferroptosis-related pathway was enriched by PEM. PEM significantly enhanced the ability of cisplatin to inhibit cell viability and proliferation in NSCLC cells. The combination of PEM and DDP synergistically induced ferroptosis, as evidenced by the increased reactive oxygen species (ROS), lipid peroxidation, and Fe 2+ and decreased SOD. PEM facilitated DDP-mediated upregulated expression of pro-ferroptosis proteins (ACSL4, 12LOX, COX2, DMT1, TFR1, and TF) and downregulated the expression of anti-ferroptosis proteins (SLC7A11, GPX4, FPN1, FTH1, FTL, DHODH, FSP1, and GCH1). However, the effects were reversed by ferroptosis inhibitor ferrostatin-1 or deferoxamine in NSCLC cells.
Conclusion
In summary, these results provide in vitro experimental evidence that PEM boosts the antitumor activity and increases the sensitivity of NSCLC cells to DDP by inducing ferroptosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
- Department of General Ward, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
Zitieren
APA
Wang, Y., Zhang, X., Cao, Y., Zhang, G., Zhu, Y., Li, Y., & Chen, J. (2026). Pemetrexed sensitizes cisplatin therapy by inducing ferroptosis in NSCLC cells. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1764937
Vancouver
Wang Y, Zhang X, Cao Y, Zhang G, Zhu Y, Li Y, et al. Pemetrexed sensitizes cisplatin therapy by inducing ferroptosis in NSCLC cells. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1764937
BibTeX
@article{Wang2026,
author = {Wang, Yumin and Zhang, Xin and Cao, Yuwei and Zhang, Ge and Zhu, Yonglin and Li, Yulin and Chen, Jichao},
title = {Pemetrexed sensitizes cisplatin therapy by inducing ferroptosis in NSCLC cells},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {16},
doi = {10.3389/fphar.2025.1764937}
}
EUVIMED